Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management

Area of Science:

• Neurology
• Sleep Medicine
• Pharmacology

Background:

• Obstructive sleep apnea (OSA) frequently causes excessive daytime sleepiness (EDS), impacting daily life.
• Continuous positive airway pressure (CPAP) therapy may not resolve EDS in all OSA patients.
• Mechanisms for persistent EDS in treated OSA are not fully understood.

Purpose of the Study:

• To review the pathophysiology, evaluation, and management of EDS in OSA patients.
• To discuss potential neurobiological underpinnings of residual EDS.
• To examine pharmacotherapeutic options for persistent EDS.

Main Methods:

• Review of existing literature on OSA, EDS, and treatment strategies.
• Discussion of neuroimaging findings related to brain alterations in OSA and EDS.
• Analysis of clinical assessment tools for EDS severity and impact.
• Evaluation of wake-promoting pharmacotherapies.

Main Results:

• Chronic intermittent hypoxia and sleep fragmentation may contribute to EDS pathophysiology.
• Neuroimaging reveals white and gray matter changes in OSA patients with EDS.
• Dopamine or dopamine/norepinephrine reuptake inhibitors show efficacy in reducing EDS.
• Pharmacotherapy can improve quality of life for OSA patients with residual EDS.

Conclusions:

• Persistent EDS in OSA requires thorough evaluation and management beyond primary treatment.
• Understanding the neurobiological basis of EDS is crucial for targeted therapies.
• Wake-promoting medications offer a viable option for managing residual EDS in OSA.
• Further research is needed on cognitive effects and personalized responses to treatment.